TheraRadar
Data updated: May 26, 2026

CEFEPIME IN PLASTIC CONTAINER (cefepime hydrochloride)

Infectious Disease Approved 2008-08-05

CEFEPIME IN PLASTIC CONTAINER is indicated for the treatment of Pneumonia; Febrile Neutropenia; Urinary Tract Infection; Skin and Skin Structure Infections; Intra-Abdominal Infection.

Source: FDA Label • Baxter

How CEFEPIME IN PLASTIC CONTAINER Works

Cefepime is a bactericidal antibacterial agent that acts by inhibiting bacterial cell wall synthesis. It exerts its effect by binding to specific penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall, which prevents the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.

1
Indication
--
Phase 3 Trials
17
Years on Market

Details

Status
Prescription
First Approved
2008-08-05
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: CEFEPIME HYDROCHLORIDE

CEFEPIME IN PLASTIC CONTAINER Approval History

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
14 FDA actions from 2008 to 2025
Jul 2025 SUPPL
Label · Labeling
May 2020 SUPPL
Label · Labeling
May 2016 SUPPL
Label · Labeling

What CEFEPIME IN PLASTIC CONTAINER Treats

5 indications

CEFEPIME IN PLASTIC CONTAINER is approved for 5 conditions since its original approval in 2008. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pneumonia
  • Febrile Neutropenia
  • Urinary Tract Infection
  • Skin and Skin Structure Infections
  • Intra-Abdominal Infection
Source: FDA Label

CEFEPIME IN PLASTIC CONTAINER Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CEFEPIME IN PLASTIC CONTAINER

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE
5 shared
CHARTWELL RX
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
CEFEPIME HYDROCHLORIDE
5 shared
SAMSON MEDCL
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
CEFEPIME HYDROCHLORIDE
4 shared
B BRAUN
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01484015 IRB00015247 NCI-2011-02422, CCCWFU 02110 Ph 1 completed Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CEFEPIME IN PLASTIC CONTAINER FDA Label Details

Indications & Usage

FDA Label (PDF)

CEFEPIME IN PLASTIC CONTAINER is indicated for the treatment of Pneumonia; Febrile Neutropenia; Urinary Tract Infection; Skin and Skin Structure Infections; Intra-Abdominal Infection.

Track CEFEPIME IN PLASTIC CONTAINER with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.